BAM
RNAM

Byrne Asset Management’s Avidity Biosciences RNAM Stock Holding History

Byrne Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,375
Closed -$93K – 576
2023
Q2 		$93K Buy
+8,375
New +$105K 0.06% 200

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Byrne Asset Management's RNAM Position: Q3 2023 in Review

Byrne Asset Management sold out of Avidity Biosciences (RNAM) in Q3 2023, closing a stake of 8,375 shares — an estimated $93K sold.

Byrne Asset Management first reported a position in RNAM in Q2 2023 and held it in 1 quarter. The position peaked at $93K in Q2 2023. 142 funds tracked by Wall St. Rank hold RNAM as of Q3 2023.

  • Byrne Asset Management reported no remaining Avidity Biosciences position as of Q3 2023 after selling out during the quarter.
  • Byrne Asset Management sold 8,375 Avidity Biosciences shares in Q3 2023, an estimated $93K.
  • Byrne Asset Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 1 quarter.
  • Byrne Asset Management's Avidity Biosciences position peaked at $93K in Q2 2023.
  • 142 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2023.

Based on Byrne Asset Management's 13F filing for Q3 2023, filed 31 Oct 2023.